Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

Articles published in
Blood
    October 2025
  1. RODDIE C, Dias J, O'Reilly MA, Abbasian M, et al
    Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion.
    Blood. 2025;146:1664-1676.
    >> Share

    September 2025
  2. PENTER L, Maurer K, Cieri N, Lu W, et al
    Mechanisms of immune escape and extramedullary tropism in leukemia cutis.
    Blood. 2025 Sep 30:blood.2025029121. doi: 10.1182/blood.2025029121.
    >> Share

  3. NEDUMANNIL R, Ashby M, Rowland J, Malherbe JAJ, et al
    Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML.
    Blood. 2025;146:1625-1629.
    >> Share

  4. DEREVYANKO PK, Swart LE, Mata Casimiro LD, van Oort A, et al
    Fusion Gene Depletion Eliminates Stemness and Induces Bidirectional Differentiation of Acute Myeloid Leukemia.
    Blood. 2025 Sep 24:blood.2025028988. doi: 10.1182/blood.2025028988.
    >> Share

  5. MATEOS-JAIMEZ J, Vidal Crespo A, Charalampopoulou S, Fernandez Perez R, et al
    INCREASED LEF1 PROTEIN LEVELS AND ISOFORM SWITCHING DRIVE CELL PROLIFERATION IN CHRONIC LYMPHOCYTIC LEUKEMIA.
    Blood. 2025 Sep 22:blood.2025030129. doi: 10.1182/blood.2025030129.
    >> Share

  6. NEVEN Q, Arfeuille C, Caye-Eude A, Durand P, et al
    The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohort.
    Blood. 2025 Sep 19:blood.2025029916. doi: 10.1182/blood.2025029916.
    >> Share

  7. ANDRICOVICH J, Lap CJ, Tzatsos A
    Loss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors.
    Blood. 2025;146:1493-1510.
    >> Share

  8. SHARMAN JP, Egyed M, Jurczak W, Skarbnik A, et al
    Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.
    Blood. 2025;146:1276-1285.
    >> Share

  9. VENKATESH H, Granados Centeno E, Luo Q, Arroyo M, et al
    Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells.
    Blood. 2025 Sep 4:blood.2024028194. doi: 10.1182/blood.2024028194.
    >> Share

  10. PAPAPETROU EP
    Breaking ribosomes to fight leukemia.
    Blood. 2025;146:1155-1156.
    >> Share

  11. DAMASKOU A, Wilson R, Gozdecka M, Giotopoulos G, et al
    Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AML.
    Blood. 2025;146:1239-1252.
    >> Share

  12. GHOBADI A, Aldoss I, Maude SL, Bhojwani D, et al
    Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies.
    Blood. 2025;146:1163-1173.
    >> Share

  13. REN H, Elliott N, Lye B, Sharif Shohan MU, et al
    Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.
    Blood. 2025 Sep 3:blood.2025029302. doi: 10.1182/blood.2025029302.
    >> Share

    August 2025
  14. CRISPINO JD
    Meddling with METTL3 in acute megakaryoblastic leukemia.
    Blood. 2025;146:1035-1036.
    >> Share

  15. GEYER MB, DeWolf S, Mi X, Weis K, et al
    CD371-Targeted CAR T cells Secreting Interleukin-18 Exhibit Robust Expansion and Clear Refractory Acute Myeloid Leukemia.
    Blood. 2025 Aug 27:blood.2025029532. doi: 10.1182/blood.2025029532.
    >> Share

  16. O'BRIEN C, Nursimulu N, Tyagi A, Culp-Hill R, et al
    Plasma lipid levels predict chemotherapy response and survival in acute myeloid leukemia.
    Blood. 2025 Aug 26:blood.2025029132. doi: 10.1182/blood.2025029132.
    >> Share

  17. CHENG W, Yi X, Wang Z, Li JF, et al
    Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.
    Blood. 2025 Aug 19:blood.2024027692. doi: 10.1182/blood.2024027692.
    >> Share

  18. MONTEFIORI LE, Iacobucci I, Gao Q, Moore J, et al
    Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia.
    Blood. 2025 Aug 14:blood.2025028985. doi: 10.1182/blood.2025028985.
    >> Share

  19. ZHOU X, Chen J, Tang YL, Sun H, et al
    Epidemiology, Clinical Features, and Molecular Basis of TTMV::RARA-driven Acute Promyelocytic Leukemia.
    Blood. 2025 Aug 14:blood.2025028674. doi: 10.1182/blood.2025028674.
    >> Share

  20. ANNESLEY C, Seidel K, Wu Q, Summers C, et al
    Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALL.
    Blood. 2025;146:789-801.
    >> Share

  21. CHEN S, Xiao Z
    Atypical cytoplasmic inclusions and erythrophagocytosis in acute myeloid leukemia with KMT2A::MLLT3 and U2AF1 mutation.
    Blood. 2025;146:765.
    >> Share

  22. ABRUZZESE E, Chelysheva E
    How I Manage Chronic Myeloid Leukemia During Pregnancy.
    Blood. 2025 Aug 4:blood.2024026513. doi: 10.1182/blood.2024026513.
    >> Share

  23. PAULI C, Kienhofer M, Blank MF, Begik O, et al
    Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells.
    Blood. 2025 Aug 1:blood.2024027822. doi: 10.1182/blood.2024027822.
    >> Share

    July 2025
  24. DAVER N, Vyas P, Huls G, Dohner H, et al
    The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy.
    Blood. 2025;146:601-611.
    >> Share

  25. SMITH A, Denny NDR, Chahrour C, Sharp K, et al
    Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients.
    Blood. 2025 Jul 29:blood.2024028019. doi: 10.1182/blood.2024028019.
    >> Share

  26. UMEDA M, Hiltenbrand RL, Michmerhuizen NL, Barajas JM, et al
    Fusion Oncoproteins and Cooperating Mutations Define Disease Phenotypes in NUP98-Rearranged Leukemia.
    Blood. 2025 Jul 23:blood.2025028993. doi: 10.1182/blood.2025028993.
    >> Share

  27. JI Y, Huang Y, Thomas T, Kapti EG, et al
    CD99 Promotes Self-renewal in Hematopoietic Stem Cells and Leukemia Stem Cells by Regulating Protein Synthesis.
    Blood. 2025 Jul 23:blood.2024026271. doi: 10.1182/blood.2024026271.
    >> Share


  28. Duployez N, Largeaud L, Duchmann M, et al. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. Blood. 2022;140(7):756-768.
    Blood. 2025;146:397.
    >> Share

  29. CHENG J, Zhou J
    Secondary blastoid plasma cell leukemia: can an old dog learn new tricks?
    Blood. 2025;146:396.
    >> Share

  30. KITTAI AS, Marchetti M, Al-Sawaf O, Benjamini O, et al
    International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.
    Blood. 2025;146:291-303.
    >> Share

  31. WANG Z, Skwarska A, Poigaialwar G, Chaudhry S, et al
    Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.
    Blood. 2025;146:341-355.
    >> Share

  32. GOEL P, Aryal S, Franceski AM, Kuznetsova V, et al
    The acute myeloid leukemia microenvironment impairs neutrophil maturation and function through NFkappaB signaling.
    Blood. 2025 Jul 15:blood.2024028199. doi: 10.1182/blood.2024028199.
    >> Share

  33. GRAINGER BT, Thompson PA, Cheah CY
    Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia.
    Blood. 2025;146:145-154.
    >> Share

  34. CARTER BZ, Mak PY, Ayoub E, Wu X, et al
    Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.
    Blood. 2025 Jul 3:blood.2025028935. doi: 10.1182/blood.2025028935.
    >> Share

  35. MOHAMED A, Richardson AI
    Therapy-related juvenile myelomonocytic leukemia.
    Blood. 2025;146:127.
    >> Share

    June 2025
  36. DEB PQ, Zhang X
    B-lymphoblastic leukemia with KMT2A rearrangement with mature B-cell phenotype and surface lambda light-chain restriction.
    Blood. 2025;145:3194.
    >> Share

  37. REVILLE PK, Wang B, Marvin-Peek J, Yuan B, et al
    Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes.
    Blood. 2025;145:3015-3029.
    >> Share

  38. LUGER SM
    Introduction to a Blood Spotlight series on acute myeloid leukemia.
    Blood. 2025;145:2801-2802.
    >> Share

  39. SELVARAJAH S, Xia D
    A small B-cell leukemia/lymphoma with weak to negative expression of CD5.
    Blood. 2025;145:2931.
    >> Share

  40. COURTOIS L, Pinton A, Cabannes-Hamy A, Simonin M, et al
    Surface pTalpha expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL.
    Blood. 2025;145:2903-2913.
    >> Share

  41. PERL AE
    Approaching a therapeutic inflection point for FLT3-mutated AML.
    Blood. 2025;145:2834-2839.
    >> Share

  42. CHEN C, Xu J, Sussman JH, Vincent T, et al
    Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcome.
    Blood. 2025;145:2685-2700.
    >> Share

  43. KATER AP, Harrup R, Kipps TJ, Eichhorst B, et al
    The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.
    Blood. 2025;145:2733-2745.
    >> Share

  44. WIERDA WG, Eichhorst BF, Hallek MJ
    Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic Lymphocytic Leukemia.
    Blood. 2025 Jun 2:blood.2025028570. doi: 10.1182/blood.2025028570.
    >> Share

    May 2025
  45. LU J, Xue SL, Wang Y, He XF, et al
    Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML.
    Blood. 2025;145:2645-2655.
    >> Share

  46. EGAN G, Tasian SK
    Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A, NUP98, and GLIS2 rearrangements.
    Blood. 2025;145:2574-2586.
    >> Share

  47. ESCHERICH CS, Li Z, Barnett KR, Li Y, et al
    Differentiation-dependent EBF1 Activity Determines CD22 Transcription and Leukemia Sensitivity to Inotuzumab Ozogamicin.
    Blood. 2025 May 28:blood.2024028215. doi: 10.1182/blood.2024028215.
    >> Share

  48. MAYDAY MY, Biancon G, Wei M, Ramirez C, et al
    RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and WNT pathway activation.
    Blood. 2025 May 28:blood.2024027712. doi: 10.1182/blood.2024027712.
    >> Share

  49. JUM'AH H, Viswanatha D
    Classic hairy cell leukemia and concomitant smoldering myeloma.
    Blood. 2025;145:2533.
    >> Share

  50. BASSAN R, Chiaretti S, Della Starza I, Santoro A, et al
    Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study.
    Blood. 2025;145:2447-2459.
    >> Share

  51. YOSHIMITSU M, Choi I, Kusumoto S, Shimokawa M, et al
    A phase 2 Trial of CHOP with Anti-CCR4 Antibody Mogamulizumab for older Patients with Adult T-Cell Leukemia/Lymphoma.
    Blood. 2025 May 15:blood.2024027902. doi: 10.1182/blood.2024027902.
    >> Share

  52. WANG X, Yi H
    Adult T-cell leukemia/lymphoma coexistent with immune dysregulation-associated EBV+ lymphoproliferative disorder.
    Blood. 2025;145:2396.
    >> Share

  53. SAORIN A, Dehler A, Galvan B, Steffen FD, et al
    Transcriptional remodeling shapes therapeutic vulnerability to necroptosis in acute lymphoblastic leukemia.
    Blood. 2025 May 13:blood.2025028938. doi: 10.1182/blood.2025028938.
    >> Share

  54. PELZL R, Benintende G, Gsottberger F, Scholz JK, et al
    Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment.
    Blood. 2025 May 13:blood.2024027877. doi: 10.1182/blood.2024027877.
    >> Share

  55. ALDOSS I, Clark MC, Forman SJ
    How I Treat: Revisiting the myth of second remission in acute lymphoblastic leukemia in the era of immunotherapy.
    Blood. 2025 May 12:blood.2024027267. doi: 10.1182/blood.2024027267.
    >> Share

  56. HOURIGAN CS
    From prognostication to precision in acute myeloid leukemia.
    Blood. 2025;145:2105-2106.
    >> Share


  57. Luskin MR, Murakami MA, Keating J, et al. Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia. Blood. 2025;145(6):577-589.
    Blood. 2025;145:2231.
    >> Share

  58. LEVIS MJ, Hamadani M, Logan BR, Jones RJ, et al
    Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
    Blood. 2025;145:2138-2148.
    >> Share

  59. GOOPTU M, Murdock HM, Soiffer RJ
    How I treat AML relapse after allogeneic HSCT.
    Blood. 2025;145:2128-2137.
    >> Share

  60. TEFFERI A, Fathima S, Abdelmagid M, Alsugair A, et al
    BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia.
    Blood. 2025 May 7:blood.2024027170. doi: 10.1182/blood.2024027170.
    >> Share

  61. ARELLANO ML, Thirman MJ, DiPersio JF, Heiblig M, et al
    Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.
    Blood. 2025 May 7:blood.2025028357. doi: 10.1182/blood.2025028357.
    >> Share

  62. BULLINGER L
    Mixed-phenotype acute leukemia revisited: omics lead the way.
    Blood. 2025;145:1969-1971.
    >> Share

    April 2025
  63. MCMAHON CM
    Beyond conVENtional 7+3 in acute myeloid leukemia.
    Blood. 2025;145:1831-1832.
    >> Share

  64. GARCIAZ S
    STINGing leukemia stem cells through PSTK inhibition.
    Blood. 2025;145:1833-1835.
    >> Share

  65. ZHANG W, Cai J, Wang X, Ma Y, et al
    Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALL.
    Blood. 2025;145:1890-1902.
    >> Share

  66. PODVIN B, Hardeman A
    Early T-precursor acute lymphoblastic leukemia with mature plasmacytoid dendritic cell proliferation.
    Blood. 2025;145:1827.
    >> Share

  67. CHAKRABORTY SR, Karrs JX
    A rare case of nodal hairy cell leukemia exhibiting characteristic morphological and immunohistochemical features.
    Blood. 2025;145:1826.
    >> Share

  68. DE KESEL J, Fijalkowski I, Pieters T, Borin C, et al
    HNRNPC and m6A RNA methylation control oncogenic transcription and metabolism in T-cell leukemia.
    Blood. 2025 Apr 15:blood.2024026848. doi: 10.1182/blood.2024026848.
    >> Share

  69. DAVIDS MS, Kenderian SS, Flinn IW, Hill BT, et al
    ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia.
    Blood. 2025 Apr 10:blood.2024027460. doi: 10.1182/blood.2024027460.
    >> Share

  70. TURHAN AG
    SMAC mimetics in action in chronic myeloid leukemia.
    Blood. 2025;145:1596-1597.
    >> Share


  71. Zhu H-H, Hu J, Lo-Coco F, Jin J. The simpler, the better: oral arsenic for acute promyelocytic leukemia. Blood. 2019;134(7):597-605.
    Blood. 2025;145:1703-1705.
    >> Share

  72. SILBERT SK, Rankin AW, Hoang CN, Semchenkova A, et al
    Project EVOLVE: An international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia.
    Blood. 2025 Apr 7:blood.2024026655. doi: 10.1182/blood.2024026655.
    >> Share

  73. DOMBRET H
    Introduction to a review series on acute lymphoblastic leukemia.
    Blood. 2025;145:1439.
    >> Share

  74. RAMPOTAS A, Roddie C
    The present and future of CAR T-cell therapy for adult B-cell ALL.
    Blood. 2025;145:1485-1497.
    >> Share

    March 2025
  75. BAKHSHI TJ, Pina-Oviedo S
    Warthin-Finkeldey cells seen in a setting other than measles: chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Blood. 2025;145:1437.
    >> Share

  76. CALO-PEREZ A, Martinez-Fernandez R
    Atypical chronic myeloid leukemia: from cytology to molecular characterization.
    Blood. 2025;145:1438.
    >> Share

  77. ROTHFUSS C, Baumann T, Donakonda S, Brauchle B, et al
    Two-layered immune escape in AML is overcome by Fcgamma receptor activation and inhibition of PGE2 signaling in NK cells.
    Blood. 2025;145:1395-1406.
    >> Share

  78. HAN Q, Gu Y, Xiang H, Zhang L, et al
    Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL.
    Blood. 2025;145:1407-1421.
    >> Share

  79. CHEN J, Suttorp M, Hijiya N
    How I treat chronic myeloid leukemia in children and adolescents.
    Blood. 2025 Mar 25:blood.2024026514. doi: 10.1182/blood.2024026514.
    >> Share

  80. KOTROVA M, Proske C, Darzentas N, Laqua A, et al
    NGS-based IG/TR rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation.
    Blood. 2025 Mar 25:blood.2024027175. doi: 10.1182/blood.2024027175.
    >> Share

  81. LUGER SM
    Introduction to a How I Treat series on acute myeloid leukemia.
    Blood. 2025;145:1227-1228.
    >> Share

  82. FURSTENAU M, Robrecht S, Schneider C, Tausch E, et al
    MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.
    Blood. 2025;145:1282-1292.
    >> Share

  83. WEI AH, Loo S, Daver N
    How I treat patients with AML using azacitidine and venetoclax.
    Blood. 2025;145:1237-1250.
    >> Share

  84. LUO Q, Fortune AL, Lane AA
    PI3Kgamma in leukemia: class IB PI3 kinase reemerges as a cancer-intrinsic target.
    Blood. 2025 Mar 19:blood.2024027376. doi: 10.1182/blood.2024027376.
    >> Share

  85. XU J, Sussman JH, Yang A, Yoshimura S, et al
    STAT1-mediated interferon signatures associate with preclinical JAK-inhibitor sensitivity in T-cell acute lymphoblastic leukemia.
    Blood. 2025 Mar 18:blood.2025028566. doi: 10.1182/blood.2025028566.
    >> Share

  86. DALGETTY M, Cortes J
    Considerations on the Dose and Schedule of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Does Dose Matter?
    Blood. 2025 Mar 18:blood.2024027944. doi: 10.1182/blood.2024027944.
    >> Share

  87. FALGAS A, Lazaro-Gorines R, Zanetti SR, Rubio-Perez L, et al
    A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia.
    Blood. 2025 Mar 16:blood.2024025440. doi: 10.1182/blood.2024025440.
    >> Share

  88. WANG WJ, Loghavi S
    Acute myeloid leukemia with RUNX1::CBFA2T3 fusion.
    Blood. 2025;145:1226.
    >> Share

  89. WULIJI N, Jones SMW, Gooley TA, Gerds AT, et al
    Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.
    Blood. 2025 Mar 11:blood.2024027543. doi: 10.1182/blood.2024027543.
    >> Share

  90. TAM CS, Balendran S, Blombery P
    Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors.
    Blood. 2025;145:1005-1009.
    >> Share

    February 2025
  91. ZEIDNER JF, Sallman DA, Recher C, Daver NG, et al
    Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.
    Blood. 2025 Feb 26:blood.2024027408. doi: 10.1182/blood.2024027408.
    >> Share

  92. TAMIRO F, Padovano C, De Santis E, Di Iasio S, et al
    NOTCH1 dimeric signaling is essential for T-cell leukemogenesis and leukemia maintenance.
    Blood. 2025 Feb 26:blood.2024027020. doi: 10.1182/blood.2024027020.
    >> Share

  93. CONDOLUCI A, Romano I, Dietrich D, Pini K, et al
    Ibrutinib Lead-in followed by Venetoclax Plus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia - SAKK 34/17.
    Blood. 2025 Feb 26:blood.2024026879. doi: 10.1182/blood.2024026879.
    >> Share

  94. ALLEN B, Bottomly D, Kohnke T, Wang A, et al
    A CEBPB/IL-1beta/TNF-alpha Feedback Loop Drives Drug Resistance to Venetoclax and MDM2 Inhibitors in Monocytic Leukemia.
    Blood. 2025 Feb 26:blood.2024028239. doi: 10.1182/blood.2024028239.
    >> Share

  95. LINDER A, Nixdorf D, Kuhl N, Piseddu I, et al
    STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia.
    Blood. 2025 Feb 26:blood.2024026934. doi: 10.1182/blood.2024026934.
    >> Share

  96. AL JABRI M, Chang H
    Blastoid variant of double-hit lymphoma masquerading as acute lymphoblastic leukemia.
    Blood. 2025;145:897.
    >> Share

  97. PARISI X, Loghavi S
    Acute erythroid leukemia or acute myeloid leukemia with mutated TP53? The battle of phenotype versus genotype.
    Blood. 2025;145:784.
    >> Share

  98. SHAH V, Giotopoulos G, Osaki H, Meyerhofer M, et al
    Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation.
    Blood. 2025;145:748-764.
    >> Share

  99. SILVA HJ, Martin G, Birocchi F, Wehrli M, et al
    CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML.
    Blood. 2025;145:720-731.
    >> Share

  100. MANTZARIS I, Goldfinger M, Uriel M, Shastri A, et al
    Venetoclax plus Daunorubicin and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia: Results of a Phase 1b Study.
    Blood. 2025 Feb 7:blood.2024026700. doi: 10.1182/blood.2024026700.
    >> Share

  101. SHEN Q, Hu S
    Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements.
    Blood. 2025;145:652.
    >> Share

  102. FISKUS W, Mill CP, Bose P, Masarova L, et al
    Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.
    Blood. 2025;145:612-624.
    >> Share

  103. HE L, Zhao T, Leong WZ, Sharda A, et al
    PSTK inhibition activates cGAS-STING, precipitating ferroptotic cell death in leukemic stem cells.
    Blood. 2025 Feb 5:blood.2024026040. doi: 10.1182/blood.2024026040.
    >> Share

    January 2025
  104. LYAPICHEV KA, Behdad A
    c-MYC stain as a potential minimal residual disease marker for acute myeloid leukemia with NPM1 mutation.
    Blood. 2025;145:547.
    >> Share

  105. POHLY MF, Putzker K, Scheinost S, Ben Taarit L, et al
    IAP dependency of T-cell prolymphocytic leukemia identified by high-throughput drug screening.
    Blood. 2025 Jan 27:blood.2024027171. doi: 10.1182/blood.2024027171.
    >> Share

  106. ABEDIN SM, Uy GL, Michaelis LC
    The Fit Older Adult with Acute Myeloid Leukemia: Clinical Challenges to Providing Evidence-Based Frontline Treatment.
    Blood. 2025 Jan 24:blood.2024026004. doi: 10.1182/blood.2024026004.
    >> Share

  107. CHAPAPRIETA V, Maiques-Diaz A, Nadeu F, Clot G, et al
    Dual Biological Role and Clinical Impact of De Novo Chromatin Activation in Chronic Lymphocytic Leukemia.
    Blood. 2025 Jan 22:blood.2024025396. doi: 10.1182/blood.2024025396.
    >> Share

  108. ALIKARAMI F, Xie HM, Riedel SS, Goodrow H, et al
    GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia.
    Blood. 2025 Jan 22:blood.2024025761. doi: 10.1182/blood.2024025761.
    >> Share

  109. LYU J, Liu Y, Liu N, Vu H, et al
    CD44-Mediated Metabolic Rewiring is A Targetable Dependency of IDH-Mutant Leukemia.
    Blood. 2025 Jan 22:blood.2024027207. doi: 10.1182/blood.2024027207.
    >> Share

  110. SCHAFER HACKENHAAR F, Refhagen N, Hagleitner MM, van Leeuwen FN, et al
    CpG island methylator phenotype classification improves risk assessment in pediatric T-cell Acute Lymphoblastic Leukemia.
    Blood. 2025 Jan 22:blood.2024026027. doi: 10.1182/blood.2024026027.
    >> Share

  111. ARAUJO JL, Wagenblast E, Voisin V, McLeod J, et al
    FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable for human hematopoietic stem cells.
    Blood. 2025 Jan 22:blood.2024025886. doi: 10.1182/blood.2024025886.
    >> Share

  112. GALERA P, Dilip D, Derkach A, Chan A, et al
    Defining 2 Biologically and Clinically Distinct Groups in Acute Leukemia with a Mixed Phenotype.
    Blood. 2025 Jan 15:blood.2024026273. doi: 10.1182/blood.2024026273.
    >> Share

  113. RONNACKER J, Grau M, Klasmeier M, Klesse C, et al
    Common Hereditary Variants of the APOE Gene and Posttransplant Outcome in Acute Myeloid Leukemia.
    Blood. 2025 Jan 15:blood.2024026886. doi: 10.1182/blood.2024026886.
    >> Share

  114. NYGREN PJ, Bouhlal JOV, Jokinen E, Forsten S, et al
    High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell cytotoxicity in chronic myeloid leukemia.
    Blood. 2025 Jan 10:blood.2024025286. doi: 10.1182/blood.2024025286.
    >> Share

  115. PURVIS K, Zhou Y, Karol SE, Rubnitz JE, et al
    Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies.
    Blood. 2025;145:190-201.
    >> Share

  116. DING YY, Sussman JH, Madden K, Loftus JP, et al
    Targeting Senescent Stemlike Subpopulations in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.
    Blood. 2025 Jan 7:blood.2024026482. doi: 10.1182/blood.2024026482.
    >> Share

  117. BASKAR S, Peng H, Gaglione EM, Carstens EJ, et al
    Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragment covalently deposited on lymphoma cells.
    Blood. 2025 Jan 7:blood.2024024846. doi: 10.1182/blood.2024024846.
    >> Share

  118. DOMBRET H
    Introduction to a How I Treat series on acute lymphoblastic leukemia.
    Blood. 2025;145:1-2.
    >> Share

  119. CHIARETTI S, Foa R
    How I treat adult Ph+ ALL.
    Blood. 2025;145:11-19.
    >> Share

  120. LAMBLE AJ, Kovach AE, Shah NN
    How I treat postimmunotherapy relapsed B-ALL.
    Blood. 2025;145:64-74.
    >> Share

    December 2024
  121. PASSET M, Kim R, Clappier E
    Genetic subtypes of B-cell acute lymphoblastic leukemia in adults.
    Blood. 2024 Dec 30:blood.2023022919. doi: 10.1182/blood.2023022919.
    >> Share

  122. CRUZ-RODRIGUEZ N, Deininger MW
    Novel Treatment Strategies for Chronic Myeloid Leukemia.
    Blood. 2024 Dec 27:blood.2024026312. doi: 10.1182/blood.2024026312.
    >> Share

  123. ESCHERICH CS, Moriyama T, Li Z, Hsiao Y, et al
    DNTT-mediated DNA Damage Response Drives Inotuzumab Ozogamicin Resistance in B-cell Acute Lymphoblastic Leukemia.
    Blood. 2024 Dec 27:blood.2024026085. doi: 10.1182/blood.2024026085.
    >> Share

  124. MILLMAN SE, Chaves-Perez A, Janaki-Raman S, Ho YJ, et al
    alpha-Ketoglutarate dehydrogenase is a therapeutic vulnerability in acute myeloid leukemia.
    Blood. 2024 Dec 27:blood.2024025245. doi: 10.1182/blood.2024025245.
    >> Share

  125. NAHARRO EF, Linden MA
    Auer rod-like inclusions in B-cell lymphoma mimicking therapy-related acute myeloid leukemia.
    Blood. 2024;144:2793.
    >> Share

  126. LACHOWIEZ CA, Ravikumar VI, Othman J, O'Nions J, et al
    Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.
    Blood. 2024;144:2788-2792.
    >> Share

  127. BROWN JR, Eichhorst B, Lamanna N, O'Brien SM, et al
    Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.
    Blood. 2024;144:2706-2717.
    >> Share

  128. HULS GA, Woolthuis CM, Schuringa JJ
    Menin inhibitors in the treatment of acute myeloid leukemia.
    Blood. 2024 Dec 24:blood.2024026232. doi: 10.1182/blood.2024026232.
    >> Share

  129. ARONS E, Tai CH, Suraj J, Liu Y, et al
    Non-V600E BRAF mutations and treatment for Hairy Cell Leukemia.
    Blood. 2024 Dec 24:blood.2024026894. doi: 10.1182/blood.2024026894.
    >> Share

  130. CUI B, Ai L, Lei M, Duan Y, et al
    Single-cell epigenetic and clonal analysis decodes disease progression in pediatric acute myeloid leukemia.
    Blood. 2024 Dec 11:blood.2024025618. doi: 10.1182/blood.2024025618.
    >> Share

  131. BOUDIA F, Baille M, Babin L, Aid Z, et al
    Progressive chromatin rewiring by ETO2::GLIS2 revealed in a human iPSC model of pediatric leukemia initiation.
    Blood. 2024 Dec 10:blood.2024024505. doi: 10.1182/blood.2024024505.
    >> Share

  132. HAUBNER S, Subklewe M, Sadelain M
    Honing CAR T cells to tackle acute myeloid leukemia.
    Blood. 2024 Dec 4:blood.2024024063. doi: 10.1182/blood.2024024063.
    >> Share

    November 2024
  133. GOLDFINGER M, Mantzaris I, Shastri A, Saunthararajah Y, et al
    A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.
    Blood. 2024;144:2360-2363.
    >> Share

  134. DOHNER H, DiNardo CD, Appelbaum FR, Craddock C, et al
    Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.
    Blood. 2024;144:2169-2173.
    >> Share

  135. DOHNER H, Pratz KW, DiNardo CD, Wei AH, et al
    Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.
    Blood. 2024;144:2211-2222.
    >> Share

  136. MA J, Wang Z, Mintzlaff D, Zhang H, et al
    Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia.
    Blood. 2024 Nov 19:blood.2024025277. doi: 10.1182/blood.2024025277.
    >> Share

  137. NAIR MS, Silbert SK, Rejeski K, Wilson KA, et al
    Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia.
    Blood. 2024 Nov 19:blood.2024025910. doi: 10.1182/blood.2024025910.
    >> Share

  138. LU P, Zhang X, Yang J, Li J, et al
    Nanobody-based Naturally Selected CD7-Targeted CAR-T Therapy for Acute Myeloid Leukemia.
    Blood. 2024 Nov 19:blood.2024024861. doi: 10.1182/blood.2024024861.
    >> Share


  139. Handa S, Lee J-O, Derkach A, et al. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy. Blood. 2022;140(25):2663-2671.
    Blood. 2024;144:2068.
    >> Share

  140. CHEVALIER S, Legrand C
    B-cell acute lymphoblastic leukemia with MEF2D::BCL9 rearrangement mimicking a Burkitt lymphoma.
    Blood. 2024;144:2067.
    >> Share

  141. HUNTER AM, Patnaik MM, Itzykson R, Mesa R, et al
    Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm.
    Blood. 2024;144:1987-1992.
    >> Share

  142. LOPEZ-MILLAN B, Rubio-Gayarre A, Vinyoles M, Trincado JL, et al
    NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression.
    Blood. 2024;144:2002-2017.
    >> Share

  143. VOSO MT, Guarnera L, Lehmann S, Dohner K, et al
    Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project.
    Blood. 2024 Nov 6:blood.2024026186. doi: 10.1182/blood.2024026186.
    >> Share

  144. GUILHOT F, Hehlmann R
    Long-term Outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia.
    Blood. 2024 Nov 1:blood.2024026311. doi: 10.1182/blood.2024026311.
    >> Share

    October 2024
  145. LUO MX, Tan T, Trussart M, Poch A, et al
    Venetoclax Dose Escalation Rapidly Activates a BAFF/BCL-2 Survival Axis in Chronic Lymphocytic Leukemia.
    Blood. 2024 Oct 29:blood.2024024341. doi: 10.1182/blood.2024024341.
    >> Share

  146. WU Q, Chen D
    Near early T-precursor lymphoblastic leukemia with marked flower petal nuclei: blast with unique cyanthiform nucleus.
    Blood. 2024;144:1846.
    >> Share

  147. KIM E, Chen SS, Sivina M, Hwang H, et al
    Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD.
    Blood. 2024 Oct 23:blood.2024025683. doi: 10.1182/blood.2024025683.
    >> Share

  148. LIU Y, Bollino DR, Bah OM, Strovel ET, et al
    A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed/refractory acute myeloid leukemia.
    Blood. 2024 Oct 22:blood.2024024837. doi: 10.1182/blood.2024024837.
    >> Share

  149. GOKBUGET N, Steffen B
    How I Treat Older Patients with Ph/BCR-ABL-Negative Acute Lymphoblastic Leukemia.
    Blood. 2024 Oct 11:blood.2023023156. doi: 10.1182/blood.2023023156.
    >> Share

  150. KWOK M, Stankovic T
    Targeting therapeutic vulnerabilities in T-PLL.
    Blood. 2024;144:1548-1550.
    >> Share

  151. NIEDER R, Li W
    Constitutive STAT5 activation in precursor B-cell acute lymphoblastic leukemia with P2RY8::CRLF2 fusion.
    Blood. 2024;144:1646.
    >> Share

  152. VON JAN J, Timonen S, Braun T, Jiang Q, et al
    Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses.
    Blood. 2024;144:1595-1610.
    >> Share

  153. SIMONIN M, Vasseur L, Lengline E, Lhermitte L, et al
    NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients.
    Blood. 2024;144:1570-1580.
    >> Share

  154. NEWMAN H, Teachey DT
    A T-ALL order: a new risk classifier for T-ALL.
    Blood. 2024;144:1545-1547.
    >> Share

  155. ROBOZ GJ, Canaani J
    How I use Maintenance Therapy in Acute Myeloid Leukemia.
    Blood. 2024 Oct 7:blood.2024024010. doi: 10.1182/blood.2024024010.
    >> Share

  156. LUSKIN MR, Murakami MA, Keating JH, Flamand Y, et al
    Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia.
    Blood. 2024 Oct 7:blood.2024025800. doi: 10.1182/blood.2024025800.
    >> Share

  157. ZHOU X, Chen X, Chen J, Wen L, et al
    Critical role of tripartite fusion and LBD truncation in certain RARA- and all RARG-related atypical APL.
    Blood. 2024;144:1471-1485.
    >> Share

  158. POLONEN P, Mullighan CG, Teachey DT
    Classification and risk stratification in T-lineage acute lymphoblastic leukemia.
    Blood. 2024 Oct 2:blood.2023022920. doi: 10.1182/blood.2023022920.
    >> Share

  159. KYTOLA S, Vanttinen IM, Ruokoranta T, Partanen A, et al
    Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial.
    Blood. 2024 Oct 2:blood.2024024968. doi: 10.1182/blood.2024024968.
    >> Share

  160. GREEN SD, Wang ES
    How I Treat: Secondary Acute Myeloid Leukemia.
    Blood. 2024 Oct 2:blood.2024024011. doi: 10.1182/blood.2024024011.
    >> Share

    September 2024
  161. POCOCK R, Mansour MR
    T-ALL and T-LBL: a notch apart.
    Blood. 2024;144:1356-1357.
    >> Share

  162. LI Z, Meng G
    Targeting DUX4-r leukemia via PI3K and CD371.
    Blood. 2024;144:1354-1356.
    >> Share

  163. SHARMAN JP
    Pirtobrutinib combinations in CLL.
    Blood. 2024;144:1351-1352.
    >> Share

  164. THORSSON H, Henningsson R, Puente-Moncada N, Pena-Martinez P, et al
    Single-cell genomics details the maturation block in BCP-ALL and identifies therapeutic vulnerabilities in DUX4-r cases.
    Blood. 2024;144:1399-1411.
    >> Share

  165. ROEKER LE, Woyach JA, Cheah CY, Coombs CC, et al
    Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial.
    Blood. 2024;144:1374-1386.
    >> Share

  166. RAHMAN S, Bloye G, Farah N, Demeulemeester J, et al
    Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia.
    Blood. 2024 Sep 24:blood.2024024300. doi: 10.1182/blood.2024024300.
    >> Share

  167. JIN Q, Harris E, Myers JA, Mehmood R, et al
    Disruption of cotranscriptional splicing suggests that RBM39 is a therapeutic target in acute lymphoblastic leukemia.
    Blood. 2024 Sep 24:blood.2024024281. doi: 10.1182/blood.2024024281.
    >> Share

  168. LOO S, Potter N, Ivey A, O'Nions J Dr, et al
    Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia.
    Blood. 2024 Sep 24:blood.2024026605. doi: 10.1182/blood.2024026605.
    >> Share

  169. WANG ES
    Curing APL in Latin America: more than just ATRA.
    Blood. 2024;144:1237-1238.
    >> Share

  170. BONADIES N
    SHERLOCK unmasks fusion-driven leukemias.
    Blood. 2024;144:1241-1243.
    >> Share

  171. VEDULA RS, Karp HQ, Koob J, Lim F, et al
    CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias.
    Blood. 2024;144:1290-1299.
    >> Share

  172. PENTER L, Wu CJ
    Therapy response in AML: a tale of two T cells.
    Blood. 2024;144:1134-1136.
    >> Share

  173. KWON MC, Thuring JW, Querolle O, Dai X, et al
    Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.
    Blood. 2024;144:1206-1220.
    >> Share

  174. WALTER RB, Potter V, Craddock C
    Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Adults over 70 years old.
    Blood. 2024 Sep 6:blood.2024024247. doi: 10.1182/blood.2024024247.
    >> Share

  175. BADAR T, Luger SM, Litzow MR
    Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia.
    Blood. 2024 Sep 5:blood.2023022921. doi: 10.1182/blood.2023022921.
    >> Share

  176. SALLMAN DA, Stahl M
    TP53-Mutated Acute Myeloid Leukemia: How Can We Improve Outcomes?
    Blood. 2024 Sep 5:blood.2024024245. doi: 10.1182/blood.2024024245.
    >> Share

  177. FALKENBURG JHF, Heemskerk MHM
    TCR targeting hematopoiesis to cure leukemia.
    Blood. 2024;144:1031-1033.
    >> Share

    August 2024
  178. SUMMERS RJ, Teachey DT
    SNPing away poor outcomes in T-ALL.
    Blood. 2024;144:924-925.
    >> Share

  179. EADIE LN, Lagonik E, Page EC, Schutz CE, et al
    Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy.
    Blood. 2024;144:1022-1026.
    >> Share

  180. BALDUCCI E, Simonin M, Duployez N, Steimle T, et al
    Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL.
    Blood. 2024;144:988-1000.
    >> Share

  181. WADHWA A, Chen Y, Hageman L, Angiolillo A, et al
    Antimetabolite Dose Intensity and Adverse Outcomes in Children with Acute Lymphoblastic Leukemia: A COG-AALL03N1 Report.
    Blood. 2024 Aug 27:blood.2024024455. doi: 10.1182/blood.2024024455.
    >> Share

  182. COBALEDA C, Sanchez-Garcia I
    Childhood leukemia prevention within reach.
    Blood. 2024;144:799-800.
    >> Share

  183. INGELFINGER F
    Hijacking T helper cells for AML progression.
    Blood. 2024;144:804-805.
    >> Share

  184. XU Z, Padmore R
    AML, myelodysplasia related, with STAG2 and SRSF2 comutations with myelocyte arrest.
    Blood. 2024;144:918.
    >> Share

  185. BHATLA T, Hogan L MD, Teachey DT, Bautista F, et al
    Daratumumab in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: DELPHINUS Study.
    Blood. 2024 Aug 16:blood.2024024493. doi: 10.1182/blood.2024024493.
    >> Share

  186. ZHOU X, Zhang L, Aryal S, Veasey V, et al
    Epigenetic Regulation of Non-canonical Menin Targets Modulates Menin Inhibitor Response in Acute Myeloid Leukemia.
    Blood. 2024 Aug 16:blood.2023023644. doi: 10.1182/blood.2023023644.
    >> Share

  187. HU Z, Ok CY
    Immature erythroblasts in pleural effusion: an initial presentation of acute erythroid leukemia in a patient with a history of MDS.
    Blood. 2024;144:794.
    >> Share

  188. ITZYKSON R
    NPM1-mutated AML: how many diseases?
    Blood. 2024;144:681-683.
    >> Share

  189. OTHMAN J, Potter N, Ivey A, Tazi Y, et al
    Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.
    Blood. 2024;144:714-728.
    >> Share

  190. LEYTE-VIDAL A, Garrido Ruiz D, DeFilippis R, Leske IB, et al
    BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.
    Blood. 2024;144:639-645.
    >> Share

  191. YEUNG DT, Shanmuganathan N, Reynolds J, Branford S, et al
    Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid Leukemia: Results from the ASCEND Study.
    Blood. 2024 Aug 5:blood.2024024657. doi: 10.1182/blood.2024024657.
    >> Share

  192. ARRIETA-BOLANOS E, van der Burg LLJ, Gedde-Dahl T, Robin M, et al
    Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS.
    Blood. 2024 Aug 5:blood.2024024351. doi: 10.1182/blood.2024024351.
    >> Share


  193. Metzeler KH, Herold T, Rothenberg-Turley M, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128(5):686-698.
    Blood. 2024;144:589.
    >> Share

  194. MOSS P
    A tumor suppressor of CLL: all (T-)bets are on.
    Blood. 2024;144:467-469.
    >> Share

  195. COOK JA, Lott L, Perry J, Eckel AM, et al
    Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML.
    Blood. 2024;144:581-585.
    >> Share

  196. EFFICACE F, Kicinski M, Coens C, Suciu S, et al
    Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial.
    Blood. 2024;144:541-551.
    >> Share

    July 2024
  197. ZHANG X, Liu B, Huang J, Zhang YL, et al
    A predictive model for therapy failure in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy.
    Blood. 2024 Jul 24:blood.2024024761. doi: 10.1182/blood.2024024761.
    >> Share

  198. TE VRUGT M, Wessolowski JS, Randau G, Alfert A, et al
    Pediatric T-cell lymphoblastic lymphoma but not leukemia harbor TRB::NOTCH1 fusions with unfavorable outcome.
    Blood. 2024 Jul 18:blood.2024025307. doi: 10.1182/blood.2024025307.
    >> Share


  199. van der Straten L, Stege CAM, Kersting S, et al. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL. Blood. 2023;142(13):1131-1142.
    Blood. 2024;144:341.
    >> Share


  200. Melnick AF, Mullin C, Lin K, et al. Cdc73 protects Notch-induced T-cell leukemia cells from DNA damage and mitochondrial stress. Blood. 2023;142(25):2159-2174.
    Blood. 2024;144:342.
    >> Share

  201. RADICH J
    Transplant, MRD, and predicting relapse in AML.
    Blood. 2024;144:245-247.
    >> Share

  202. OPAT S
    Treatment of relapsed CLL "in the BAAG"?
    Blood. 2024;144:243-244.
    >> Share

  203. MUFFLY L, Liang EC, Dolan JG, Pulsipher MA, et al
    How I use next-generation sequencing-MRD to plan approach and prevent relapse after HCT for children and adults with ALL.
    Blood. 2024;144:253-261.
    >> Share

  204. FURSTENAU M, Giza A, Weiss J, Kleinert F, et al
    Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial.
    Blood. 2024;144:272-282.
    >> Share

  205. WEI Q, Xu J
    Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib.
    Blood. 2024;144:238.
    >> Share

  206. HOURIGAN CS
    How complete must an AML remission be?
    Blood. 2024;144:131-132.
    >> Share

  207. AL-SAWAF O, Robrecht S, Zhang C, Olivieri S, et al
    Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study.
    Blood. 2024 Jul 10:blood.2024024631. doi: 10.1182/blood.2024024631.
    >> Share

  208. ISSA GC, Stein EM, DiNardo CDD
    How I Treat: Differentiation Therapy in Acute Myeloid Leukemia.
    Blood. 2024 Jul 8:blood.2024024008. doi: 10.1182/blood.2024024008.
    >> Share

  209. SUO S, Zhao D, Li F, Zhang Y, et al
    Homoharringtonine Inhibits the NOTCH/MYC Pathway and Exhibits Anti-Tumor Effects in T-Cell Acute Lymphoblastic Leukemia.
    Blood. 2024 Jul 5:blood.2023023400. doi: 10.1182/blood.2023023400.
    >> Share

  210. SRINAGESH HK, Jackson C, Shiraz P, Jeyakumar N, et al
    A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.
    Blood. 2024 Jul 5:blood.2024024952. doi: 10.1182/blood.2024024952.
    >> Share

  211. LUM SH, Eikema DJ, Piepenbroek B, Wynn R, et al
    Outcome of Hematopoietic Stem Cell Transplantation in 813 Pediatric Patients with Fanconi Anemia.
    Blood. 2024 Jul 5:blood.2023022751. doi: 10.1182/blood.2023022751.
    >> Share

  212. QIAN Z, Yu F
    GADD45A: a key tumor suppressor in AML subtypes.
    Blood. 2024;144:6-7.
    >> Share

  213. ZHAO Y, Short NJ, Kantarjian HM, Chang TC, et al
    Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
    Blood. 2024;144:61-73.
    >> Share

    June 2024
  214. RADPOUR R, Simillion C, Wang B, Abbas HA, et al
    IL-9 Secreted by Leukemia Stem Cells Induces Th1-Skewed CD4+ T-Cells, which Promote Their Expansion.
    Blood. 2024 Jun 28:blood.2024024000. doi: 10.1182/blood.2024024000.
    >> Share

  215. BIDOT S, Feldman AL
    Herpetic lymphadenitis mimicking Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Blood. 2024;143:2808.
    >> Share

  216. LENK L, Baccelli I, Laqua A, Heymann J, et al
    The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis.
    Blood. 2024;143:2735-2748.
    >> Share

  217. LIN HY, Mohammadhosseini M, McClatchy J, Villamor-Paya M, et al
    The TLK-ASF1 histone chaperone pathway plays a critical role in IL-1beta-mediated AML progression.
    Blood. 2024;143:2749-2762.
    >> Share

  218. WALCZAK P, Fodil S, Vignal N, Cabannes-Hamy A, et al
    Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1-positive acute lymphoblastic leukemia.
    Blood. 2024 Jun 25:blood.2024024838. doi: 10.1182/blood.2024024838.
    >> Share

  219. BARTRAM J, Ancliff P, Vora A
    How I Treat on Infant Acute Lymphoblastic Leukemia.
    Blood. 2024 Jun 21:blood.2023023154. doi: 10.1182/blood.2023023154.
    >> Share


  220. Garcia E, Horowitz AM, Franklin K, Mader M, Kaur S. Outcomes of veterans with FMS-like tyrosine kinase 3 mutated (mFLT3) acute myeloid leukemia (AML) treated with novel FLT3 inhibitors (FLT3i) within the Veterans Health Administration (VHA) [abstract]
    Blood. 2024;143:2676.
    >> Share

  221. FORCONI F
    Time for a new prognostic score in CLL?
    Blood. 2024;143:2561-2562.
    >> Share

  222. GAO Q, Harrison CJ
    B-ALL with intrachromosomal amplification of chromosome 21 in a carrier of the Robertsonian translocation rob(14;21)c.
    Blood. 2024;143:2672.
    >> Share

  223. SATO T, Yoshida K, Toki T, Kanezaki R, et al
    Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms.
    Blood. 2024;143:2627-2643.
    >> Share

  224. FARROKHI A, Atre T, Salitra S, Aletaha M, et al
    Early-life infection depletes preleukemic cells in a mouse model of hyperdiploid B-cell acute lymphoblastic leukemia.
    Blood. 2024 Jun 14:blood.2024025038. doi: 10.1182/blood.2024025038.
    >> Share

  225. SANZ J, Labopin M, Choi G, Kulagin A, et al
    Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT.
    Blood. 2024;143:2534-2543.
    >> Share

  226. MARCHAND T, Lamy de La Chapelle T, Loughran TP
    A modern view of LGL leukemia.
    Blood. 2024 Jun 7:blood.2023021790. doi: 10.1182/blood.2023021790.
    >> Share

  227. LUSKIN MR
    Finding the perPh+ect balance in Ph+ ALL.
    Blood. 2024;143:2339-2340.
    >> Share

    May 2024
  228. KANG YA
    Awakening your innate power to combat AML.
    Blood. 2024;143:2223-2224.
    >> Share

  229. HALL T, Gurbuxani S, Crispino JD
    Malignant progression of preleukemic disorders.
    Blood. 2024;143:2245-2255.
    >> Share

  230. ONIDA F, Gagelmann N, Chalandon Y, Kobbe G, et al
    Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee.
    Blood. 2024;143:2227-2244.
    >> Share

  231. KOURY LCA, Kim HT, Undurraga MS, Navarro-Cabrera JR, et al
    Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia.
    Blood. 2024 May 28:blood.2024023890. doi: 10.1182/blood.2024023890.
    >> Share

  232. BRINKMANN BJ, Floerchinger A, Schniederjohann C, Roider T, et al
    CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models.
    Blood. 2024 May 28:blood.2023022682. doi: 10.1182/blood.2023022682.
    >> Share

  233. SAWYER EM, Kraft AS
    SMACing down relapsed T-ALL.
    Blood. 2024;143:2116-2117.
    >> Share

  234. MAZZIOTTA F, Biavati L, Rimando JC, Rutella S, et al
    CD8+ T-cell Differentiation and Dysfunction Inform Treatment Response in Acute Myeloid Leukemia.
    Blood. 2024 May 22:blood.2023021680. doi: 10.1182/blood.2023021680.
    >> Share

  235. LEWIS RI, Vom Stein AF, Hallek MJ
    Targeting the tumor microenvironment for treating double refractory chronic lymphocytic leukemia.
    Blood. 2024 May 22:blood.2023022861. doi: 10.1182/blood.2023022861.
    >> Share

  236. WOYACH JA, Jones D, Jurczak W, Robak T Prof, et al
    Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib.
    Blood. 2024 May 16:blood.2023023659. doi: 10.1182/blood.2023023659.
    >> Share


  237. MRD and EFS in pediatric T-lymphoblastic lymphoma.
    Blood. 2024;143:2111.
    >> Share


  238. Silva A, Almeida ARM, Cachucho A, et al. Overexpression of wild-type IL-7Ralpha promotes T-cell acute lymphoblastic leukemia/lymphoma. Blood. 2021;138(12):1040-1052.
    Blood. 2024;143:2108-2110.
    >> Share

  239. RIBERA JM
    MRD: also for T-lymphoblastic lymphoma.
    Blood. 2024;143:2017-2019.
    >> Share

  240. TAMENI A, Toffalori C, Vago L
    Tricking the Trickster: Precision Medicine Approaches to Counteract Leukemia Immune Escape after Transplant.
    Blood. 2024 May 10:blood.2023019962. doi: 10.1182/blood.2023019962.
    >> Share

  241. LE RQ, Przepiorka D, Chen H, Shen YL, et al
    Complete Remission with Partial Hematological Recovery as a Palliative Endpoint for Treatment of Acute Myeloid Leukemia.
    Blood. 2024 May 10:blood.2023023313. doi: 10.1182/blood.2023023313.
    >> Share

  242. RECHER C
    Transplant in AML: just follow the NPM1 guide!
    Blood. 2024;143:1881-1882.
    >> Share

  243. SUNG PJ
    PIKing the right target in AML.
    Blood. 2024;143:1884-1885.
    >> Share

  244. OTHMAN J, Potter N, Ivey A, Jovanovic J, et al
    Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
    Blood. 2024;143:1931-1936.
    >> Share

  245. GOKBUGET N, Boissel N, Chiaretti S, Dombret H, et al
    Management of ALL in adults: 2024 ELN recommendations from a European expert panel.
    Blood. 2024;143:1903-1930.
    >> Share

  246. GOKBUGET N, Boissel N, Chiaretti S, Dombret H, et al
    Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel.
    Blood. 2024;143:1891-1902.
    >> Share

    April 2024
  247. ROESSNER PM, Seufert I, Chapaprieta V, Jayabalan R, et al
    T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia.
    Blood. 2024 Apr 29:blood.2023021990. doi: 10.1182/blood.2023021990.
    >> Share

  248. KRAKOW EF, Brault M, Summers C, Cunningham TM, et al
    HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
    Blood. 2024 Apr 29:blood.2024024105. doi: 10.1182/blood.2024024105.
    >> Share

  249. WIENECKE CP, Heida B, Venturini L, Gabdoulline R, et al
    Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation.
    Blood. 2024 Apr 26:blood.2023022697. doi: 10.1182/blood.2023022697.
    >> Share

  250. SUBKLEWE M
    T cells take aim in AML: targeting IDH2.
    Blood. 2024;143:1681-1682.
    >> Share

  251. ABDELBAKY SB, Giacopelli B, Rabe KG, Yamaguchi K, et al
    Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature.
    Blood. 2024;143:1752-1757.
    >> Share

  252. TRAN TH, Tasian SK
    How I Treat Philadelphia Chromosome-like Acute Lymphoblastic Leukemia in Children, Adolescents, and Young Adults.
    Blood. 2024 Apr 24:blood.2023023153. doi: 10.1182/blood.2023023153.
    >> Share

  253. LAMBLE AJ, Rau RE
    IFN-gamma and CD38 in AML: a T-cell engagement made in heaven?
    Blood. 2024;143:1556-1557.
    >> Share

  254. CUNEO A, Ghia P
    Ibrutinib in CLL: benefit for all?
    Blood. 2024;143:1558-1559.
    >> Share

  255. BUFFET R
    How lipid coating soothes the gut in AML therapy.
    Blood. 2024;143:1559-1561.
    >> Share

  256. RENGA G, Nunzi E, Stincardini C, Pariano M, et al
    CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis.
    Blood. 2024;143:1628-1645.
    >> Share

  257. WOYACH JA, Perez Burbano G, Ruppert AS, Miller C, et al
    Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
    Blood. 2024;143:1616-1627.
    >> Share

  258. LANGERBEINS P, Giza A, Robrecht S, Cramer P, et al
    Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
    Blood. 2024 Apr 15:blood.2023022564. doi: 10.1182/blood.2023022564.
    >> Share

  259. BULLINGER L, Kronke J
    Making AML fly too close to the sun.
    Blood. 2024;143:1438-1439.
    >> Share

  260. BOURGEOIS W, Cutler JA, Aubrey BJ, Wenge DV, et al
    Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
    Blood. 2024;143:1513-1527.
    >> Share

  261. KROEZE E, Iaccarino I, Kleisman MM, Mondal M, et al
    Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma.
    Blood. 2024 Apr 8:blood.2024023938. doi: 10.1182/blood.2024023938.
    >> Share

  262. HASSAN N, Yi H, Malik B, Gaspard-Boulinc LC, et al
    Loss of stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML.
    Blood. 2024 Apr 5:blood.2024024072. doi: 10.1182/blood.2024024072.
    >> Share

  263. MARCAIS A
    Targeting PD-L1 to treat ATLL?
    Blood. 2024;143:1320-1322.
    >> Share

  264. MINA A, Greenberg PL, Deeg HJ
    How I reduce and treat posttransplant relapse of MDS.
    Blood. 2024;143:1344-1354.
    >> Share

  265. BASTIAN L, Beder T, Barz MJ, Bendig S, et al
    Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
    Blood. 2024;143:1391-1398.
    >> Share

    March 2024
  266. INESS AN, Bachireddy P
    GPR56 in GVL: marker or mechanism?
    Blood. 2024;143:1206-1207.
    >> Share

  267. MATHIOUDAKI A, Wang X, Sedloev D, Huth R, et al
    The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature.
    Blood. 2024;143:1269-1281.
    >> Share

  268. BAUMGARTNER F, Baer C, Bamopoulos S, Ayoub E, et al
    Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022.
    Blood. 2024;143:1139-1156.
    >> Share

  269. KLEIN K, Kollmann S, Hiesinger A, List J, et al
    A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia.
    Blood. 2024 Mar 18:blood.2023022655. doi: 10.1182/blood.2023022655.
    >> Share

  270. AZOULAY E, Maertens J, Lemiale V
    How I manage acute respiratory failure in patients with hematological malignancies.
    Blood. 2024;143:971-982.
    >> Share

  271. MACK EA, Dougher MC, Ginda AM, Cahill C, et al
    Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis.
    Blood. 2024;143:1049-1054.
    >> Share

  272. FELIPE FUMERO E, Walter C, Frenz JM, Seifert FC, et al
    Epigenetic control over cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia.
    Blood. 2024 Mar 8:blood.2023021640. doi: 10.1182/blood.2023021640.
    >> Share

  273. HAYASHI RJ, Hermiston ML, Wood BL, Teachey DT, et al
    MRD at the End of Induction and EFS in T-cell Lymphoblastic Lymphoma: Children's Oncology Group Trial AALL1231.
    Blood. 2024 Mar 8:blood.2023021184. doi: 10.1182/blood.2023021184.
    >> Share

  274. CHALANDON Y, Rousselot P, Chevret S, Cayuela JM, et al
    Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia.
    Blood. 2024 Mar 7:blood.2023023502. doi: 10.1182/blood.2023023502.
    >> Share


  275. Colom Diaz PA, Mistry JJ, Trowbridge JJ. Hematopoietic stem cell aging and leukemia transformation. Blood. 2023;142(6):533-542.
    Blood. 2024;143:939.
    >> Share

  276. AHMED R, Feldman AL
    Occult ALK-negative anaplastic large cell lymphoma complicating chronic lymphocytic leukemia.
    Blood. 2024;143:938.
    >> Share

  277. O'CONNOR D, Valle-Inclan JE, Conde L, Bloye G, et al
    Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL.
    Blood. 2024;143:933-937.
    >> Share

  278. ESCHERICH CS, Chen W, Li Y, Yang W, et al
    Germline Genetic NBN Variation and Predisposition to B-cell Acute Lymphoblastic Leukemia in Children.
    Blood. 2024 Mar 6:blood.2023023336. doi: 10.1182/blood.2023023336.
    >> Share

  279. AVILA AVILA A, Nuantang K, Oliveira ML, Druillennec S, et al
    Targeting the TNF/IAP pathway synergizes with anti-CD3 immunotherapy in T-Cell Acute Lymphoblastic Leukemia.
    Blood. 2024 Mar 4:blood.2023022455. doi: 10.1182/blood.2023022455.
    >> Share

    February 2024
  280. BARROS PINTO MP, Cabecadas J
    Binucleated and cloverleaf-shaped nucleus in lymphocytes in CLL.
    Blood. 2024;143:833.
    >> Share

  281. MURTADHA M, Park M, Zhu Y, Caserta E, et al
    CD38-directed, single-chain T cell-engager targets leukemia stem cells through IFNgamma-induced CD38 expression.
    Blood. 2024 Feb 26:blood.2023021570. doi: 10.1182/blood.2023021570.
    >> Share

  282. VAN OUTERSTERP I, Tasian SK, Reichert CE, Boeree A, et al
    Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: The role of kinase type and SH3 domain.
    Blood. 2024 Feb 23:blood.2023023120. doi: 10.1182/blood.2023023120.
    >> Share

  283. BARBOSA K, Deshpande A, Perales M, Xiang P, et al
    Transcriptional control of leukemogenesis by the chromatin reader SGF29.
    Blood. 2024;143:697-712.
    >> Share

  284. BISWAS J, Abdel-Wahab O
    A new SAGA for AML: targeting SGF29 in AML.
    Blood. 2024;143:657-658.
    >> Share

  285. SUMMERS RJ, Teachey DT, Hunger SP
    How I treat early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) in children.
    Blood. 2024 Feb 16:blood.2023023155. doi: 10.1182/blood.2023023155.
    >> Share

  286. MENSURADO S, Condeco AC, Sanchez-Martinez D, Shirley S, et al
    CD155/PVR determines Acute Myeloid Leukemia targeting by Delta One T cells.
    Blood. 2024 Feb 16:blood.2023022992. doi: 10.1182/blood.2023022992.
    >> Share

  287. FISKUS W, Piel J, Collins MP, Hentemann M, et al
    BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor.
    Blood. 2024 Feb 16:blood.2023022832. doi: 10.1182/blood.2023022832.
    >> Share

  288. COTY-FATTAL Z, Richardson AI
    A 3-year-old with chronic myeloid leukemia.
    Blood. 2024;143:651.
    >> Share

  289. BARAJAS JM, Rasouli M, Umeda M, Hiltenbrand R, et al
    Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors.
    Blood. 2024;143:619-630.
    >> Share

  290. BERNT KM
    Menin dependence: UBTF-ITD AML joins the club.
    Blood. 2024;143:567-569.
    >> Share

  291. CHEN B, Abdel-Wahab O
    Targeting the cBAF complex in T-ALL.
    Blood. 2024;143:566-567.
    >> Share

  292. ARBER C
    Two to tango: engineered T cells against AML.
    Blood. 2024;143:476-478.
    >> Share

  293. QIU L, Naresh KN
    Mature plasmacytoid dendritic cell proliferation in association with mixed-phenotype acute leukemia, T/myeloid.
    Blood. 2024;143:561.
    >> Share

  294. DAO T, Xiong G, Mun SS, Meyerberg J, et al
    A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML.
    Blood. 2024;143:507-521.
    >> Share

  295. BHATT VR, Uy GL, Klepin HD
    Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action.
    Blood. 2024;143:483-487.
    >> Share

  296. ROUSSELOT P
    Old rivals become new friends.
    Blood. 2024;143:380-382.
    >> Share

  297. ORDONEZ MAZARIEGOS EE, Dimopoulos YP
    A rare case of ICUS progressing to MDS with isolated isochromosome 17q and AML.
    Blood. 2024;143:473.
    >> Share

    January 2024
  298. GU H, Chen C, Hou ZS, He XD, et al
    PI3Kgamma maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway.
    Blood. 2024 Jan 25:blood.2023022202. doi: 10.1182/blood.2023022202.
    >> Share

  299. SCHRAW JM
    Anticancer drug exposure in utero and leukemia.
    Blood. 2024;143:293-294.
    >> Share

  300. BARATA JT
    Darwin, MSI2, and relapse in T-ALL.
    Blood. 2024;143:294-296.
    >> Share

  301. SAHASRABUDHE KD, Mims AS
    MRD in AML: who, what, when, where, and how?
    Blood. 2024;143:296-298.
    >> Share

  302. OTHMAN J, Tiong IS, O'Nions J, Dennis M, et al
    Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.
    Blood. 2024;143:336-341.
    >> Share

  303. LEUNG WK, Torres Chavez AG, French-Kim M, Shafer P, et al
    Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia.
    Blood. 2024 Jan 19:blood.2023021979. doi: 10.1182/blood.2023021979.
    >> Share

  304. WEINACHT KG
    The rise of haplo: a quest for the perfect graft.
    Blood. 2024;143:193-195.
    >> Share


  305. alphabetaT/CD19-depleted haploHSCT for pediatric leukemia.
    Blood. 2024;143:291.
    >> Share

  306. CHEN H, Wang H
    Acute myeloid leukemia with GATA2 and WT1 mutations mimicking acute promyelocytic leukemia.
    Blood. 2024;143:290.
    >> Share

  307. SAULTIER P, Michel G
    How I Treat: long-term survivors of childhood acute leukemia.
    Blood. 2024 Jan 16:blood.2023019804. doi: 10.1182/blood.2023019804.
    >> Share

  308. BULDINI B, Varotto E, Maurer-Granofszky M, Gaipa G, et al
    CD371+ pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment.
    Blood. 2024 Jan 12:blood.2023021952. doi: 10.1182/blood.2023021952.
    >> Share


  309. Bamezai S, Pulikkottil AJ, Yadav T, et al. A noncanonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML. Blood. 2023;142(1):90-105.
    Blood. 2024;143:184.
    >> Share

  310. DIMOPOULOS YP, Loghavi S
    Acute leukemia of ambiguous lineage with BCL11B rearrangement.
    Blood. 2024;143:183.
    >> Share

  311. GHORASHIAN S, Lucchini G, Richardson R, Nguyen K, et al
    CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.
    Blood. 2024;143:118-123.
    >> Share

  312. VELTMAAT L, Cortes J
    Arterio-Occlusive Events Among Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitors.
    Blood. 2024 Jan 9:blood.2023022403. doi: 10.1182/blood.2023022403.
    >> Share

  313. MOSS P
    Ibrutinib reversal of immune exhaustion in CLL.
    Blood. 2024;143:5-7.
    >> Share


  314. Kennedy E, Coulter E, Halliwell E, et al. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood. 2021;137(22):3064-3078.
    Blood. 2024;143:93.
    >> Share

  315. PAPAZOGLOU D, Wang XV, Shanafelt TD, Lesnick CE, et al
    Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial.
    Blood. 2024;143:57-63.
    >> Share

    December 2023
  316. QUESSADA J, Loosveld M
    CBFB::MYH11 fusion in a nonmonocytic acute myeloid leukemia.
    Blood. 2023;142:2332.
    >> Share

  317. HASSERJIAN RP, Germing U, Malcovati L
    Diagnosis and classification of myelodysplastic syndromes.
    Blood. 2023;142:2247-2257.
    >> Share

  318. DEZERN AE, Greenberg PL
    The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.
    Blood. 2023;142:2258-2267.
    >> Share

  319. CHIBA M, Shimono J, Suto K, Ishio T, et al
    Whole genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in Adult T-cell leukemia/lymphoma.
    Blood. 2023 Dec 24:blood.2023021423. doi: 10.1182/blood.2023021423.
    >> Share

  320. BRECCIA M
    A traffic light for TFR by lineage-specific MRD.
    Blood. 2023;142:2129-2130.
    >> Share

  321. FU L, Gong S
    KMT2A-rearranged B-lymphoblastic leukemia/lymphoma with surface light chain restriction and lacking immature markers.
    Blood. 2023;142:2220.
    >> Share


  322. NIH natural history study of FPDMM patients.
    Blood. 2023;142:2222.
    >> Share

  323. FRANK D, Patnana PK, Vorwerk J, Mao L, et al
    Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.
    Blood. 2023;142:2175-2191.
    >> Share

  324. CUNNINGHAM L, Merguerian M, Calvo KR, Davis J, et al
    Natural history study of patients with familial platelet disorder with associated myeloid malignancy.
    Blood. 2023;142:2146-2158.
    >> Share

  325. MARCELLINO BK
    PPM1D inhibition may allow us to WIP leukemia.
    Blood. 2023;142:2040-2042.
    >> Share

  326. COUSTAN-SMITH E, Conter V
    Closing the circle for ETP ALL.
    Blood. 2023;142:2039-2040.
    >> Share

  327. WOOD BL, Devidas M, Summers RJ, Chen Z, et al
    Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study.
    Blood. 2023;142:2069-2078.
    >> Share

  328. DIMITRIOU M, Mortera-Blanco T, Tobiasson M, Mazzi S, et al
    Identification and surveillance of rare relapse-initiating stem cells during complete remission post-transplantation.
    Blood. 2023 Dec 14:blood.2023022851. doi: 10.1182/blood.2023022851.
    >> Share

  329. PALM-APERGI C
    PLK4, a potential target against AML.
    Blood. 2023;142:1941-1942.
    >> Share

  330. STONE RM
    FLT(3)-ing about: the search for the best inhibitor.
    Blood. 2023;142:1937-1938.
    >> Share

  331. MAN CH, Lam W, Dang CC, Zeng XY, et al
    Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML.
    Blood. 2023;142:2002-2015.
    >> Share

  332. FLEMING S, Tsai XC, Morris R, Hou HA, et al
    TP53 status and impact on AML prognosis within the ELN 2022 risk classification.
    Blood. 2023;142:2029-2033.
    >> Share

  333. LOO S, Roberts AW, Anstee NS, Kennedy GA, et al
    Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
    Blood. 2023;142:1960-1971.
    >> Share

    November 2023
  334. BEWERSDORF JP, How J, Masarova L, Bose P, et al
    Moving toward disease modification in polycythemia vera.
    Blood. 2023;142:1859-1870.
    >> Share

  335. DAVIDS MS
    Functional cure reported in CLL.
    Blood. 2023;142:1761-1763.
    >> Share

  336. LIN E, Chen W
    Acute myeloid leukemia with NUP98::HOXA9 mimicking acute promyelocytic leukemia.
    Blood. 2023;142:1845.
    >> Share


  337. Wei AH, Panayiotidis P, Montesinos P, et al. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood. 2022;140(25):2754-2756.
    Blood. 2023;142:1846-1847.
    >> Share

  338. THOMPSON PA, Bazinet A, Wierda WG, Tam CS, et al
    Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.
    Blood. 2023;142:1784-1788.
    >> Share

  339. KIM R, Bergugnat H, Pastoret C, Pasquier F, et al
    Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study.
    Blood. 2023;142:1806-1817.
    >> Share

  340. ROLLIG C
    Gemtuzumab ozogamicin in AML: the next chapter.
    Blood. 2023;142:1673-1674.
    >> Share

  341. STRASSER B, Haushofer A
    Cabot rings in chronic myelomonocytic leukemia.
    Blood. 2023;142:1757.
    >> Share

  342. FREEMAN SD, Thomas A, Thomas I, Hills RK, et al
    Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
    Blood. 2023;142:1697-1707.
    >> Share


  343. Fractionated vs single-dose gemtuzumab for AML.
    Blood. 2023;142:1759.
    >> Share

  344. BUENO C, Torres-Ruiz R, Velasco-Hernandez T, Molina O, et al
    A human genome editing-based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features.
    Blood. 2023;142:1752-1756.
    >> Share

  345. THOL FR, Dohner H, Ganser A
    How I treat refractory and relapsed acute myeloid leukemia.
    Blood. 2023 Nov 9:blood.2023022481. doi: 10.1182/blood.2023022481.
    >> Share

  346. VYAS P
    Changing treatment changing prognosis of mutations.
    Blood. 2023;142:1583-1585.
    >> Share

  347. AOKI K, Hyuga M, Tarumoto Y, Nishibuchi G, et al
    Canonical BAF complex regulates the oncogenic program in human T-cell acute lymphoblastic leukemia.
    Blood. 2023 Nov 3:blood.2023020857. doi: 10.1182/blood.2023020857.
    >> Share

    October 2023
  348. JABBOUR EJ, Haddad FG, Short NJ, Senapati J, et al
    Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission.
    Blood. 2023 Oct 25:blood.2023022330. doi: 10.1182/blood.2023022330.
    >> Share

  349. MALAGA ML, Carrillo LF
    FISH-negative, karyotype-negative acute promyelocytic leukemia.
    Blood. 2023;142:1328.
    >> Share

  350. PRINCE HM
    Blocked addiction to IL-15 for treating T-LGLL.
    Blood. 2023;142:1258-1260.
    >> Share

  351. XIE J, Bao X, Xue SL, Shen H, et al
    Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML.
    Blood. 2023;142:1323-1327.
    >> Share

  352. ZHANG J, Duan Y, Wu P, Chang Y, et al
    Clonal Evolution Dissection Reveals High MSI2 Level Promotes Chemo-resistance in T-cell Acute Lymphoblastic Leukemia.
    Blood. 2023 Oct 6:blood.2023020490. doi: 10.1182/blood.2023020490.
    >> Share

  353. KUMAR J, Petrova-Drus K
    Acute leukemia with predominantly myeloid differentiation and TBL1XR1::CSF1R fusion.
    Blood. 2023;142:1253.
    >> Share

  354. CHELOOR KOVILAKAM S, Gu M, Dunn WG, Marando L, et al
    Prevalence and significance of DDX41 gene variants in the general population.
    Blood. 2023;142:1185-1192.
    >> Share

  355. YAMAMOTO S, Sanefuji M, Suzuki M, Sonoda Y, et al
    Pediatric leukemia and maternal occupational exposure to anticancer drugs: The Japan Environment and Children's Study.
    Blood. 2023 Oct 3:blood.2023021008. doi: 10.1182/blood.2023021008.
    >> Share

    September 2023
  356. GOEDE V
    Frailty is also a target for targeted drugs in CLL.
    Blood. 2023;142:1107-1108.
    >> Share

  357. VAN DER STRATEN L, Stege CAM, Kersting S, Nasserinejad K, et al
    Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
    Blood. 2023;142:1131-1142.
    >> Share

  358. MERLI P, Algeri M, Galaverna F, Bertaina V, et al
    TCRalphabeta/CD19 cell-depleted HLA-haploidentical transplantation to treat pediatric acute leukemia: updated final analysis.
    Blood. 2023 Sep 22:blood.2023021336. doi: 10.1182/blood.2023021336.
    >> Share

  359. LI S, Adams PD
    Targeting the epichaperome to combat AML.
    Blood. 2023;142:1031-1032.
    >> Share


  360. Gribben JG. Targeting the methylome to improve CLL outcome. Blood. 2023;142(1):4-6.
    Blood. 2023;142:1103.
    >> Share

  361. CARTER BZ, Mak PY, Muftuoglu M, Tao W, et al
    Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
    Blood. 2023;142:1056-1070.
    >> Share

  362. UCKELMANN HJ, Klusmann JH
    Double trouble: IRAK1/4 inhibitors in AML/MDS.
    Blood. 2023;142:945-946.
    >> Share

  363. KWOK M, Stankovic T
    CLL patients: GIVe me three!
    Blood. 2023;142:941-943.
    >> Share

  364. HUBER H, Tausch E, Schneider C, Edenhofer S, et al
    Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
    Blood. 2023;142:961-972.
    >> Share

  365. BENNETT J, Ishikawa C, Agarwal P, Yeung J, et al
    Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML.
    Blood. 2023;142:989-1007.
    >> Share

  366. FEI MY, Wang Y, Chang BH, Xue K, et al
    The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment.
    Blood. 2023;142:903-917.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016